A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report

Uemura,Kei-Ichiro; Nakagawa,Go; Chikui,Katsuaki; Moriya,Fukuko; Nakiri,Makoto; Hayashi,Tokumasa; Suekane,Shigetaka; Matsuoka,Kei

doi:10.3892/ol.2013.1136

March 2013 Volume 5 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March 2013 Volume 5 Issue 3

Full Size Image

Case Report

A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report

Authors:
- Kei-Ichiro Uemura
- Go Nakagawa
- Katsuaki Chikui
- Fukuko Moriya
- Makoto Nakiri
- Tokumasa Hayashi
- Shigetaka Suekane
- Kei Matsuoka
View Affiliations / Copyright

Affiliations: Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan
Pages: 793-796
|
Published online on: January 15, 2013

https://doi.org/10.3892/ol.2013.1136
Expand metrics +

Abstract

Treating extended prostatic small cell neuroendocrine carcinoma (PSCNC) is extremely difficult and no standard treatment has yet been established. We experienced a case of advanced mixed-type PSCNC in which the patient achieved long-term survival and local control following combined therapy. Locally advanced PSCNC causing lower urinary obstruction was detected during androgen-ablation therapy for stage D2 mixed adenocarcinoma PSCNC. The patient was treated with intra-arterial infusion chemotherapy using a reservoir system and external-beam radiotherapy (EBRT) to the whole pelvis and local tumor. After chemoradiotherapy, the patient's lower urinary obstruction was reduced and did not return during the remaining 40 months of the patient's life. The patient survived for 70 months following the start of the androgen-ablation therapy. The present study reports a useful treatment for advanced mixed-type PSCNC, androgen-ablation therapy and chemoradiotherapy. The present results also suggest that the prognostic factors for advanced mixed-type PSCNC are the sensitivity of the conventional adenocarcinoma to androgen-ablation therapy, degree of metastasis and extent of the small cell neuroendocrine carcinoma component.

View Figures

View References

1	Palmgren JS, Karavadia SS and Wakefield MR: Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol. 34:22–29. 2007. View Article : Google Scholar : PubMed/NCBI
2	Yao JL, Huang J and di Sant’Agnese PA: Small cell carcinoma of the prostate. Diagn Histopathol. 14:117–121. 2008. View Article : Google Scholar
3	Haider K, Shahid RK, Finch D, et al: Extra pulmonary small cell carcinoma: a Canadian province’s experience. Cancer. 107:2262–2269. 2006.
4	Levenson RM Jr, Ihde DC, Matthews MJ, Cohen MH, Gazdar AF, Bunn PA Jr and Minna JD: Small cell carcinoma presenting as an extrapulmonary neoplasm: sites of origin and response to chemotherapy. J Natl Cancer Inst. 67:607–612. 1981.PubMed/NCBI
5	Remic SC and Ruckdeschel JC: Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol. 20:89–99. 1992. View Article : Google Scholar : PubMed/NCBI
6	Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O and Shimazaki J: Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol. 8:431–436. 2001. View Article : Google Scholar : PubMed/NCBI
7	Oesterling JE, Hauzeur CG and Farrow GM: Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol. 147:804–807. 1992.PubMed/NCBI
8	Papandreou CN, Daliani DD, Thall PF, et al: Result of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 20:3072–3080. 2002. View Article : Google Scholar : PubMed/NCBI
9	Di Sant’Agnese PA and Cockett AT: The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol. 152:1927–1931. 1994.
10	Deorah S, Rao MB, Raman R, Gaitonde K and Donovan JF: Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based study. BJU Int. 109:824–830. 2012.
11	Spiess PE, Pettaway CA, Vakar-Lopez F, et al: Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 110:1729–1737. 2007. View Article : Google Scholar : PubMed/NCBI
12	Yao JL, Mardeb R and Bourne P: Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 30:705–712. 2006. View Article : Google Scholar : PubMed/NCBI
13	van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
14	Uemura K, Nishihara K, Hayashi T, Tomiyasu K and Matsuoka K: Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide. J Infect Chemother. 18:753–755. 2012. View Article : Google Scholar
15	Früh M, Kacsir B, Ess S, Cerny T, Rodriguez R and Plassnilm L: Extrapulmonary small cell carcinoma: an indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol. 187:561–567. 2011.PubMed/NCBI
16	Walenkamp AM, Sonke GS and Sleijfer DT: Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 35:228–236. 2009. View Article : Google Scholar : PubMed/NCBI
17	Vashchenko N and Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 47:147–155. 2005. View Article : Google Scholar : PubMed/NCBI
18	Feng S, Agoulnik IU, Truong A, et al: Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 17:1021–1033. 2010. View Article : Google Scholar : PubMed/NCBI